These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
756 related articles for article (PubMed ID: 22922424)
1. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424 [TBL] [Abstract][Full Text] [Related]
2. Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. Lu L; Sun HC; Zhang W; Chai ZT; Zhu XD; Kong LQ; Wang WQ; Zhang KZ; Zhang YY; Zhang QB; Ao JY; Li JQ; Wang L; Wu WZ; Tang ZY PLoS One; 2013; 8(5):e65023. PubMed ID: 23741443 [TBL] [Abstract][Full Text] [Related]
3. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma. Wang H; Xu L; Zhu X; Wang P; Chi H; Meng Z Oncol Rep; 2014 Oct; 32(4):1465-72. PubMed ID: 25070581 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Xia H; Ooi LL; Hui KM Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579 [TBL] [Abstract][Full Text] [Related]
5. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells. Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275 [TBL] [Abstract][Full Text] [Related]
6. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412 [TBL] [Abstract][Full Text] [Related]
7. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients. Wang RY; Chen L; Chen HY; Hu L; Li L; Sun HY; Jiang F; Zhao J; Liu GM; Tang J; Chen CY; Yang YC; Chang YX; Liu H; Zhang J; Yang Y; Huang G; Shen F; Wu MC; Zhou WP; Wang HY Gastroenterology; 2013 Dec; 145(6):1436-48.e1-12. PubMed ID: 23933603 [TBL] [Abstract][Full Text] [Related]
8. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089 [TBL] [Abstract][Full Text] [Related]
9. PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1α expression and protein stability. Liu Y; Zhang JB; Qin Y; Wang W; Wei L; Teng Y; Guo L; Zhang B; Lin Z; Liu J; Ren ZG; Ye QH; Xie Y Hepatology; 2013 Aug; 58(2):692-705. PubMed ID: 23505027 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839 [TBL] [Abstract][Full Text] [Related]
11. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312 [TBL] [Abstract][Full Text] [Related]
12. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation. Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566 [TBL] [Abstract][Full Text] [Related]
13. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Arao T; Ueshima K; Matsumoto K; Nagai T; Kimura H; Hagiwara S; Sakurai T; Haji S; Kanazawa A; Hidaka H; Iso Y; Kubota K; Shimada M; Utsunomiya T; Hirooka M; Hiasa Y; Toyoki Y; Hakamada K; Yasui K; Kumada T; Toyoda H; Sato S; Hisai H; Kuzuya T; Tsuchiya K; Izumi N; Arii S; Nishio K; Kudo M Hepatology; 2013 Apr; 57(4):1407-15. PubMed ID: 22890726 [TBL] [Abstract][Full Text] [Related]
14. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1. Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877 [TBL] [Abstract][Full Text] [Related]
15. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Feng YX; Wang T; Deng YZ; Yang P; Li JJ; Guan DX; Yao F; Zhu YQ; Qin Y; Wang H; Li N; Wu MC; Wang HY; Wang XF; Cheng SQ; Xie D Hepatology; 2011 Feb; 53(2):483-92. PubMed ID: 21274870 [TBL] [Abstract][Full Text] [Related]
16. Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments. Godin C; Dupont S; Ezzoukhry Z; Louandre C; Chatelain D; Henaut L; Sabbagh C; Regimbeau JM; Maziere JC; Barbare JC; Chauffert B; Galmiche A Anticancer Res; 2013 Apr; 33(4):1415-20. PubMed ID: 23564781 [TBL] [Abstract][Full Text] [Related]
17. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice. Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751 [TBL] [Abstract][Full Text] [Related]
18. Suppression of actopaxin impairs hepatocellular carcinoma metastasis through modulation of cell migration and invasion. Ng L; Tung-Ping Poon R; Yau S; Chow A; Lam C; Li HS; Chung-Cheung Yau T; Law WL; Pang R Hepatology; 2013 Aug; 58(2):667-79. PubMed ID: 23504997 [TBL] [Abstract][Full Text] [Related]
19. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal. Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Wang R; Zhao N; Li S; Fang JH; Chen MX; Yang J; Jia WH; Yuan Y; Zhuang SM Hepatology; 2013 Aug; 58(2):642-53. PubMed ID: 23468064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]